Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapy
- 1 April 2005
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 7 (4) , 297-300
- https://doi.org/10.1016/j.ccr.2005.04.005
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosisOncogene, 2004
- Rheb Binds Tuberous Sclerosis Complex 2 (TSC2) and Promotes S6 Kinase Activation in a Rapamycin- and Farnesylation-dependent MannerJournal of Biological Chemistry, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Blocking Oncogenic Ras Signaling for Cancer TherapyJNCI Journal of the National Cancer Institute, 2001
- The Farnesyltransferase Inhibitor, FTI-2153, Blocks Bipolar Spindle Formation and Chromosome Alignment and Causes Prometaphase Accumulation during Mitosis of Human Lung Cancer CellsJournal of Biological Chemistry, 2001
- Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the MicrotubulesJournal of Biological Chemistry, 2000
- THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICSAnnual Review of Pharmacology and Toxicology, 1997
- CAAX Geranylgeranyl Transferase Transfers Farnesyl as Efficiently as Geranylgeranyl to RhoBPublished by Elsevier ,1995
- Prenyl proteins in eukaryotic cells: a new type of membrane anchorTrends in Biochemical Sciences, 1990
- Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogeneNature, 1983